zPREDICTA
acquired by Predictive OncologyYC S15San Francisco, US · Founded 2014 · 2 employees · 1 known investors
Find your way into zPREDICTA
269 people in our graph share verified history with the zPREDICTA team — schools, employers, funds. One of them is your warm intro.
Garry Tanunlockedknows Mukti Parikh · together at Y Combinator (overlapped)
×8knows the team · via Y Combinator
knows the team · via Insight Data Science
×2knows the team · via Natera
zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.
Also known as Ixchel Scientific
Founders & leadership· Y Combinator alumni (S15)
zPREDICTA was founded in 2014 by Mukti Parikh.
MP
Mukti ParikhinCo-founder, Chief Scientific Officer (YC S15, Acquired by Predictive Oncology)2015–2019Mukti Parikh developed machine learning models for pharmaceutical R&D at OneThree Biotech and previously co-founded zPREDICTA, where he created patented 3D cell culture platforms for oncology drug testing before the company's acquisition by Predictive Oncology. He holds expertise in data science, cancer biology, and scaling AI/ML applications in life sciences.
Investors · 1
The YC application· Summer 2015 batch
What they told YC
- How long have each of you been working on this? How much of that has been full-time? Please explain.
- The founders spent the last four years developing, testing, and validating their PD-3D model in cell culture and two animal models. The work involved no software development.
- What is your company going to make? Please describe your product and what it does or will do.
- The company's Patient-Derived 3D Tissue Culture (PD-3D) platform is a ready-to-use, organ-specific system that reproduces the human tissue environment to test drug candidates and drug combinations before human trials. It targets biotechnology and pharmaceutical customers, and the founders state that incorporating it into preclinical testing can cut drug development timelines and costs by 15-35%.
Summarized from the founders' answers on their Y Combinator profile.
In the news
Frequently asked questions
- What does zPREDICTA do?
- zPREDICTA manufactures three-dimensional tissue culture models derived from patient samples that recreate human organ microenvironments for drug testing. Pharmaceutical companies and researchers use the models to evaluate cancer drug candidates and predict clinical efficacy before human trials.
- Who founded zPREDICTA?
- zPREDICTA was founded by Mukti Parikh in 2014.
- Who are zPREDICTA's investors?
- zPREDICTA's investors include Y Combinator.
- Who acquired zPREDICTA?
- zPREDICTA was acquired by Predictive Oncology.
- Where is zPREDICTA headquartered?
- zPREDICTA is headquartered in San Francisco, US.